FDA Approved Products
6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
AGRYLIN
anagrelide hydrochloride
LOE Approaching
Takeda
ORAL · CAPSULE
thrombocythemiasecondary to myeloproliferative neoplasms+3
1997
NDA30/100
AIR
air
Launch
INHALATION · GAS
2026
NDA30/100
AK-FLUOR 10%
fluorescein
LOE Approaching
INTRAVENOUS · INJECTABLE
diagnostic fluorescein angiographyangioscopy of the retina+1
2008
NDA30/100
AK-FLUOR 25%
fluorescein
LOE Approaching
INTRAVENOUS · INJECTABLE
diagnostic fluorescein angiographyangioscopy of the retina+1
2008
NDA30/100
AKINETON
biperiden hydrochloride
LOE Approaching
AbbVie
ORAL · TABLET
1959
NDA30/100
AKINETON
biperiden lactate
LOE Approaching
AbbVie
INJECTION · INJECTABLE
1961
NDA30/100
AKNE-MYCIN
erythromycin
LOE Approaching
Bausch + Lomb
TOPICAL · OINTMENT
the following infections caused by Chlamydia trachomatis : conjunctivitis of the newbornpneumonia of infancy+6
1985
NDA30/100
AKOVAZ
ephedrine sulfate
Peak
INTRAVENOUS · SOLUTION
clinically important hypotension occurring in the setting of anesthesia
2016
NDA30/100
AKTIPAK
benzoyl peroxide; erythromycin
LOE Approaching
Biofrontera
TOPICAL · GEL
2000
NDA30/100
ALAMAST
pemirolast potassium
LOE Approaching
Santen
OPHTHALMIC · SOLUTION/DROPS
1999
NDA30/100
ALAVERT
loratadine
LOE Approaching
ORAL · TABLET, ORALLY DISINTEGRATING
these symptoms due to hay feverother upper respiratory allergies: runny nose sneezing itchy+2
2002
NDA30/100
ALAWAY
ketotifen fumarate
LOE Approaching
Bausch + Lomb
OPHTHALMIC · SOLUTION/DROPS
2006
NDA30/100
ALBAMYCIN
novobiocin sodium
LOE Approaching
Pfizer
ORAL · CAPSULE
1964
NDA30/100
ALBENZA
albendazole
LOE Approaching
ORAL · TABLET
parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapewormTaenia solium+5
1996
SMNDA30/100
ALCOHOL 5% AND DEXTROSE 5%
alcohol; dextrose
LOE Approaching
B. Braun
INJECTION · INJECTABLE
1946
NDA30/100
ALDACTAZIDE
spironolactone and hydrochlorothiazide
LOE Approaching
Pfizer
ORAL · TABLET
hypertensionto lower blood pressure+15
1961
NDA30/100
ALDACTONE
spironolactone
LOE Approaching
Pfizer
ORAL · TABLET
NYHA Class III–IV heart failurereduced ejection fraction to increase survival+17
1960
NDA30/100
ALDARA
imiquimod
LOE Approaching
Bausch + Lomb
TOPICAL · CREAM
1997
NDA30/100
ALDOCLOR-150
chlorothiazide; methyldopa
LOE Approaching
Merck & Co.
ORAL · TABLET
pregnancyjust+3
1968
NDA30/100
ALDOCLOR-250
chlorothiazide; methyldopa
LOE Approaching
Merck & Co.
ORAL · TABLET
pregnancyjust+3
1968
NDA30/100
ALDOMET
methyldopa
LOE Approaching
Merck & Co.
ORAL · TABLET
Hypertension
1962
NDA30/100
ALDOMET
methyldopate hydrochloride
LOE Approaching
Merck & Co.
INJECTION · INJECTABLE
1962
NDA30/100
ALDOMET
methyldopa
LOE Approaching
Merck & Co.
ORAL · SUSPENSION
Hypertension
1981
NDA30/100
ALDORIL 15
hydrochlorothiazide; methyldopa
LOE Approaching
Merck & Co.
ORAL · TABLET
hypertension
1962
NDA30/100